Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NCT04801966 · Peter MacCallum Cancer Centre, Australia · NA · terminated · last registry update 2023-05-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low recruitment” | – | Registry record, Peter MacCallum Cancer Centre, Australia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-06Also stopped (terminated): Academic and Community Cancer Research United, Binimetinib + Encorafenib (NCT04390243)
- 2024-04-03Phase 3 first posted: Erasca, Inc., Naporafenib + Dacarbazine (NCT06346067)
- 2024-04-02Results posted on the registry: Turning Point Therapeutics, Inc., TPX-0005 + Trametinib (NCT05071183)
- 2024-04-02Also stopped (terminated): Turning Point Therapeutics, Inc., TPX-0005 + Trametinib (NCT05071183)
- 2024-03-25Also stopped (withdrawn): Saint Petersburg State University, Russia, Dabrafenib + Trametinib (NCT04739566)
- 2024-03-18Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT03551626)
- 2024-03-13Results posted on the registry: Pfizer, LGX818 + MEK162 (NCT01543698)
- 2024-03-06Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Encorafenib + Binimetinib (NCT03973918)
- 2024-03-05Results posted on the registry: Pfizer, LGX818 + MEK162 (NCT02159066)
- 2024-03-04Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Abiraterone (NCT03878524)
- 2024-02-08Results posted on the registry: Hoffmann-La Roche, Cobimetinib + Atezolizumab (NCT03625141)
- 2024-02-01Also stopped (suspended): ImmVira Pharma Co. Ltd, T3011 + Cobimetinib (NCT05756556)
- 2024-01-23Results posted on the registry: Academic and Community Cancer Research United, Binimetinib + Encorafenib (NCT04390243)
- 2024-01-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Alectinib + Alpelisib (NCT05238831)
- 2023-12-22Also stopped (withdrawn): Roswell Park Cancer Institute, Binimetinib + Palbociclib (NCT04870034)
- 2023-12-12Also stopped (terminated): Craig L Slingluff, Jr, BRAF inhibitor + 6MHP (NCT02382549)
- 2023-12-05Results posted on the registry: National Cancer Institute (NCI), Selumetinib Sulfate (NCT02839720)
- 2023-11-18Also stopped (withdrawn): University of Louisville, Dabrafenib + Trametinib (NCT02143050)
- 2023-11-18Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cobimetinib (NCT02649972)
- 2023-10-30Results posted on the registry: Pfizer, encorafenib + binimetinib (NCT03915951)
- 2023-10-30Also stopped (terminated): Pfizer, MEK162, MEK inhibitor; oral + Physician's choice chemotherapy (NCT01849874)
- 2023-10-10Phase 3 first posted: Verastem, Inc., avutometinib + Defactinib (NCT06072781)
- 2023-09-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, Trametinib 0.5 mg + Trametinib 1 MG (NCT03704688)
- 2023-09-08Results posted on the registry: Massachusetts General Hospital, Pembrolizumab + Dabrafenib (NCT03149029)
- 2023-08-04Results posted on the registry: National Cancer Institute (NCI), Trametinib Dimethyl Sulfoxide (NCT04439357)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision